GROINSS-V III
13 februari 2023
Studiecoördinator Prof. Dr. A.K.L. Reyners Afdeling Medische Oncologie Tel.: 050 3612821 (secretariaat Oncologie) E-mail: a.k.l.reyners@umcg.nl
Archief
HARBOR
6 mei 2021
Identifying subgroups with High cArdiovascular Risk in Breast cancer survivORs. Protocolnummer: NL49405.031.14 (M14HAR) METc nummer: 2014/544 Samenvatting De HARBOR-studie bestudeert en vergelijkt de prevalentie van (sub)klinische cardiovasculaire schade…
HERTHENA-PanTumor01 U31402-277
7 augustus 2025
Studiecoördinator Prof. dr. J.A. Gietema Afdeling Medische Oncologie Tel.: 050 3612821 (secretariaat Oncologie) E-mail: j.a.gietema@umcg.nl
IMA402-101 studie
13 december 2024
A phase I/II First In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific Tcell-Engaging Receptor Molecule (TCER) targeting PRAME, in Patients with…
IMA402-101 studie
25 september 2025
A phase I/II First In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific Tcell-Engaging Receptor Molecule (TCER) targeting PRAME, in Patients with…
IMGN151-1001
23 juli 2025
Open-label, fase 1- dosisescalatie en uitbreidingsstudie van IMGN151 (een anti-FRα geneesmiddel-antilichaamconjugaat) bij volwassen patiënten met recidiverende gynaecologische kankers. Samenvatting De studie betreft een Fase1, open-label dosis-escalatie- en uitbreidingsstudie,…
Immunocore IMC-F106C-101 / PRAME
1 november 2023
Inhibrx Ph1 INBRX-109
17 april 2025
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Protocol Number: Ph1 INBRX-109 (Study…
Inhibrx Ph1 INBRX-109
9 mei 2025
InvestiCAT-iPSC
6 mei 2021
Investigating cardiovascular adverse events related to cancer treatment: a study of extreme toxicity using induced pluripotent stem cells. METc nummer: 2017/395 Onderzoekscode t.b.v. borstkanker deel: O234 Samenvatting De…
Knowledge and attitudes regarding healthy lifestyle
12 april 2021
KO-TIP-007
KRT-232-103
20 september 2022
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT)Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy,…
Kwaliteit van leven immunotherapie
12 april 2021
Quality of life, cognitive function, and physical fitness of melanoma and NSCLC patients surviving more than 2 years after immune checkpoint inhibitor therapy Protocolnummer: 201800146 Eudract nummer: METc…
Kwaliteit van leven immunotherapie
LAG-3
7 januari 2022
ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemipliamb with or without platinum-based chemotherapy. Samenvatting 89Zr-DFO-REGN3767 is een experimentele PET…
M17TDM
6 mei 2021
M17TDM: Therapeutic drug monitoring for oral anti-cancer drugs Protocolnummer: M17TDM Samenvatting Orale doelgerichte medicijnen tegen kanker vormen een nieuwe groep geneesmiddelen. Op dit moment krijgen alle patiënten dezelfde…
Mariane
22 april 2024
Multicenter phase 1b/2 trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANE Samenvatting Dit is een adaptieve, dosis-escalerende, niet-gerandomiseerde, multicentrische, open-label fase Ib/II-studie…
MELFIB studie
21 februari 2025
Officiële titel: Measuring effects of high-fiber dried chicory root on the gut microbiota of patients with an intermediate to high-risk cutaneous melanoma: an explorative study. In de MELFIB…
MK2870-020
3 januari 2025
A Phase 3 Randomized, Active-Controlled, Open-label, Multicenter Study to Compare the Efficacy and Safey of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with…